Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. AbbVie Inc.
  6. News
  7. Summary
    ABBV   US00287Y1091

ABBVIE INC.

(ABBV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AbbVie : Says Medical Journal Shows Rinvoq as Better Atopic Dermatitis Treatment Than Dupixent

08/04/2021 | 02:38pm EDT


© MT Newswires 2021
All news about ABBVIE INC.
09/16ABBVIE : Files Regulatory Applications in US and Europe for Upadacitinib to Trea..
MT
09/16ABBVIE : Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ..
PR
09/16AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib for th..
CI
09/16AbbVie Submits Regulatory Applications for Treatment of Ulcerative Colitis
DJ
09/15China's biotech sector comes of age with big licensing deals, global ambition..
RE
09/14ABBVIE : and REGENXBIO Announce Eye Care Collaboration
AQ
09/14REGENXBIO : RBC Lifts Price Target on REGENXBIO to $55 From $50, Sees Eye Care D..
MT
09/13Health Care Stocks Still Adding to Afternoon Slide
MT
09/13Health Care Stocks Slipping Monday Afternoon
MT
09/13REGENXBIO : Partners with AbbVie to Commercialize RGX-314 for Retinal Eye Diseas..
MT
More news
Analyst Recommendations on ABBVIE INC.
More recommendations
Financials (USD)
Sales 2021 56 247 M - -
Net income 2021 12 652 M - -
Net Debt 2021 66 393 M - -
P/E ratio 2021 14,6x
Yield 2021 4,76%
Capitalization 190 B 190 B -
EV / Sales 2021 4,57x
EV / Sales 2022 4,09x
Nbr of Employees 48 000
Free-Float 98,0%
Chart ABBVIE INC.
Duration : Period :
AbbVie Inc. Technical Analysis Chart | ABBV | US00287Y1091 | MarketScreener
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 107,73 $
Average target price 125,48 $
Spread / Average Target 16,5%
EPS Revisions
Managers and Directors
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman-Management Board & President
Robert A. Michael Chief Financial Officer & Executive Vice President
Thomas J. Hudson Chief Scientific Officer, Senior VP-R&D
Azita Saleki-Gerhardt Executive Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ABBVIE INC.0.54%190 378
JOHNSON & JOHNSON4.68%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.20.81%246 078
NOVO NORDISK A/S50.80%232 556
ELI LILLY AND COMPANY36.28%208 604